A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015Phase 2/3Active, not recruiting
- Lead sponsor
- Regeneron Pharmaceuticals (Industry)
- Enrollment
- 160 (actual)
- Start date
- 8 Aug 2023
- Primary completion
- 16 Jan 2030 (estimated)
- Study completion
- 23 Dec 2031
- Last update posted
- 15 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 5
Interventions
- fianlimab Drug
- cemiplimab Drug
- Pemetrexed Drug
- Paclitaxel Drug
- Carboplatin Drug
- Cisplatin Drug
- Placebo Drug
Conditions and primary outcome
- Non-small Cell Lung Cancer
Primary outcome
Objective response rate (ORR) as assessed by blinded independent review committee (BICR) using RECIST 1.1 (Up to 136 Weeks); Overall Survival (OS) (Up to 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05800015.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05800015 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.